+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Familial Adenomatous Polyposis - Market Insight, Epidemiology and Market Forecast - 2030

  • ID: 5387742
  • Report
  • July 2021
  • Region: Global
  • 109 pages
  • DelveInsight

FEATURED COMPANIES

  • Emtora Biosciences
  • SLA Pharma
This ‘Familial Adenomatous Polyposis (FAP) Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the Familial Adenomatous Polyposis (FAP), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Familial Adenomatous Polyposis (FAP) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted FAP symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Familial Adenomatous Polyposis (FAP) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030

Familial Adenomatous Polyposis (FAP) Disease Understanding and Treatment Algorithm

Familial Adenomatous Polyposis (FAP) Overview

Familial adenomatous polyposis (FAP) is a rare inherited cancer predisposition syndrome characterized by hundreds to thousands of precancerous colorectal polyps (adenomatous polyps). If left untreated, affected individuals inevitably develop colon and/or rectum cancer at a relatively young age. In addition, an increased risk exists for the development of other malignancies.

FAP is caused by mutations in the adenomatous polyposis coli (APC) gene. The mutations interfere with the protein's function made by the gene, allowing cells to grow uncontrolled and predispose them to become cancers. Most patients with FAP inherit a mutation in APC from one of their parents, who were also affected by the condition. About 25% of the time, the mutation occurs when a patient is conceived, and in this case, there is no family history of FAP in the parents.

Classic FAP is characterized by hundreds to thousands of colorectal adenomatous polyps, with polyps appearing in the teen years or early 20s. Without colectomy, affected individuals usually develop colorectal cancer by the third or fourth decade of life. FAP is also associated with an increased risk for cancer of the small intestine, including the duodenum, and cancer of the thyroid, pancreas, liver (hepatoblastoma), central nervous system (CNS), and bile ducts; however, these typically occur in less than 10% of affected individuals.

FAP is passed from generation to generation in a family. Genetic alterations in the APC gene present at birth are linked to FAP, AFAP, Gardner syndrome, and Turcot syndrome. This type of change to a gene can also be called a genetic mutation, gene alteration, pathogenic or likely pathogenic germline variant, or a disruptive gene change. A genetic alteration that disrupts the function of the APC gene gives a person an increased lifetime risk of developing multiple colorectal polyps (from tens to hundreds), as well as colorectal cancer and/or other cancers of the digestive tract.

Most patients with FAP are diagnosed through family screening as either of their parents has the condition. In the majority, genetic testing is generally done in teenagers. In those families where a causative mutation has not been identified, endoscopic surveillance should start at around this age. Screening for FAP at a younger age is not recommended for ethical reasons. As the intervention is rarely required before the mid-to-late teens, it is not considered appropriate to test children long before when necessary - when a delay would not affect their management and allow them to be involved in counseling and decision making.

Blood tests are available to look for disruptive changes in the APC gene and/or MUTYH gene if FAP or its subtypes are suspected. If an alteration is found in the APC gene, other family members may be diagnosed with FAP or its subtypes if tested and have the same gene mutation.

The mainstay of this condition's management is the surgical removal of the large bowel as, except in very rare cases of attenuated FAP, it is still not possible to manage a large number of adenomas endoscopically.

Desmoid tumors are benign but may cause problems by compressing organs and/or blood vessels in the abdomen. These are treated variously with surgery, NSAIDs, anti-estrogen medications, chemotherapy and/or radiation, depending on the details in each case.

Familial Adenomatous Polyposis (FAP) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Familial Adenomatous Polyposis (FAP) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Familial Adenomatous Polyposis (FAP) market report gives a thorough understanding of FAP symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides FAP symptoms of treatment algorithms and treatment guidelines for FAP symptoms in the US, Europe, and Japan.

Familial Adenomatous Polyposis (FAP) Epidemiology

The epidemiology division's Familial Adenomatous Polyposis (FAP) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Familial Adenomatous Polyposis (FAP) epidemiology segmented as the Prevalent Cases of Familial Adenomatous Polyposis, Diagnosed cases of Familial Adenomatous Polyposis, Etiology-specific Prevalence of Familial Adenomatous Polyposis, Type-specific Prevalence of Familial Adenomatous Polyposis. The report includes the Cases of FAP in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Familial Adenomatous Polyposis (FAP) Epidemiology

The epidemiology segment also provides the Familial Adenomatous Polyposis (FAP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total 7MM cases of Familial Adenomatous Polyposis (FAP) were 60,661 in 2020.

Familial Adenomatous Polyposis (FAP) Drug Chapters

The drug chapter segment of the Familial Adenomatous Polyposis (FAP) report encloses the detailed analysis of FAP marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Familial Adenomatous Polyposis (FAP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Currently, there is no specific effective treatment available for patients with FAP, and therefore treatment is based on organ support and treatment of associated complications. When FAP is associated with a precipitating factor (i.e., bacterial infections, GI bleeding, alcoholism, and drug toxicity), early identification and treatment of the precipitating factor are essential. However, this may not prevent the development or the worsening of the syndrome. In addition, in up to 40% of patients, a precipitating factor may not be identified. Moreover, available data suggest that although the precipitating factor may be the trigger of FAP, it may not be an essential predictor of prognosis.

Familial Adenomatous Polyposis (FAP) Emerging Drugs

eRapa (encapsulated rapamycin) is a patented, micro-encapsulated formulation of Rapamycin that protects the active ingredient from rapid, low-pH degradation in the stomach. The eRapa drug product consists of sub-micron rapamycin particles incorporated into poly (methyl methacrylate) polymer. Currently, Emotra Bioscience is conducting the Phase II trial to treat Prevent Progression in FAP Patients.

Familial Adenomatous Polyposis (FAP) Market Outlook

The Familial Adenomatous Polyposis (FAP) market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Familial Adenomatous Polyposis (FAP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Familial Adenomatous Polyposis (FAP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Familial Adenomatous Polyposis (FAP) market in 7MM is expected to change in the study period 2018-2030.

Key Findings

This section includes a glimpse of the Familial Adenomatous Polyposis (FAP) market in 7MM. The market size of FAP in the seven major markets was found to be USD 33.8 million in 2020, and the market is estimated to increase at a CAGR of 18.69% for the study period (2018-2030).

The United States Market Outlook

This section provides a total of Familial Adenomatous Polyposis (FAP) market size and market size by therapies in the United States.

The United States accounts for the highest FAP market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Familial Adenomatous Polyposis (FAP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Familial Adenomatous Polyposis (FAP) market size and market size by therapies in Japan are also mentioned.

Familial Adenomatous Polyposis (FAP) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018-2030. The analysis Familial Adenomatous Polyposis (FAP) market uptake by drugs, patient uptake by therapies, and drug sales.

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Familial Adenomatous Polyposis (FAP) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Familial Adenomatous Polyposis (FAP) key players involved in developing targeted therapeutics.

Major players include eRapa (Emtora Biosciences), CPP-1X/sul (Cancer Prevention Pharmaceuticals) being and Eicosapentaenoic acid (SLA Pharma) assessed as potential therapies to be available in the market in the coming future.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Familial Adenomatous Polyposis (FAP) emerging therapies.

Reimbursement Scenario in Familial Adenomatous Polyposis (FAP)
While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient's claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working Familial Adenomatous Polyposis (FAP) domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Familial Adenomatous Polyposis (FAP) market trends. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

The publisher performs a Competitive and Market Intelligence analysis of the Familial Adenomatous Polyposis (FAP) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Familial Adenomatous Polyposis (FAP) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Familial Adenomatous Polyposis (FAP) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Familial Adenomatous Polyposis (FAP) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Familial Adenomatous Polyposis (FAP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Familial Adenomatous Polyposis (FAP) market
Report Highlights
  • In the coming years, Familial Adenomatous Polyposis (FAP) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Familial Adenomatous Polyposis (FAP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for FAP. The launch of emerging therapies will significantly impact the Familial Adenomatous Polyposis (FAP)market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for FAP.
  • The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Familial Adenomatous Polyposis (FAP) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Familial Adenomatous Polyposis (FAP) Pipeline Analysis
  • Familial Adenomatous Polyposis (FAP) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Familial Adenomatous Polyposis (FAP) Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
  • Familial Adenomatous Polyposis (FAP) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Familial Adenomatous Polyposis (FAP) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What was the Familial Adenomatous Polyposis (FAP) Market share (%) distribution in 2020, and how would it look in 2030?
  • What would be the Familial Adenomatous Polyposis (FAP) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021-2030)?
  • What are the market's key findings across 7MM, and which country will have the largest Familial Adenomatous Polyposis (FAP) market Size during the forecast period (2021-2030)?
  • At what CAGR, the Familial Adenomatous Polyposis (FAP) market is expected to grow by 7MM during the forecast period (2021-2030)?
  • What would be the Familial Adenomatous Polyposis (FAP) market outlook across the 7MM during the forecast period (2021-2030)?
  • What would be the Familial Adenomatous Polyposis (FAP) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risk, burden, and unmet needs of Familial Adenomatous Polyposis (FAP)?
  • What is the historical Familial Adenomatous Polyposis (FAP) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Familial Adenomatous Polyposis (FAP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Familial Adenomatous Polyposis (FAP)?
  • Out of all 7MM countries, which country would have the highest Cases of Familial Adenomatous Polyposis (FAP) population during the forecast period (2021-2030)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2021-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Familial Adenomatous Polyposis (FAP)?
  • What are the current treatment guidelines for treating Familial Adenomatous Polyposis (FAP) in the USA, Europe, and Japan?
  • What are the Familial Adenomatous Polyposis (FAP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Familial Adenomatous Polyposis (FAP)?
  • How many therapies are developed by each company for the treatment of Familial Adenomatous Polyposis (FAP)?
  • How many emerging therapies are in the mid-stage and late development stages to treat Familial Adenomatous Polyposis (FAP)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Familial Adenomatous Polyposis (FAP) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Familial Adenomatous Polyposis (FAP) and their status?
  • What are the key designations that have been granted for the emerging therapies for Familial Adenomatous Polyposis (FAP)?
  • What are the global historical and forecasted markets of Familial Adenomatous Polyposis (FAP)?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Familial Adenomatous Polyposis (FAP) market
  • To understand the future market competition in the Familial Adenomatous Polyposis (FAP) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Familial Adenomatous Polyposis (FAP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Familial Adenomatous Polyposis (FAP) market
  • To understand the future market competition in the Familial Adenomatous Polyposis (FAP) market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Emtora Biosciences
  • SLA Pharma
1 Key Insights

2 Report Introduction

3 Familial Adenomatous Polyposis Market Overview at a Glance
3.1 Market Share (%) Distribution of Familial Adenomatous Polyposis in 2018
3.2 Market Share (%) Distribution of Familial Adenomatous Polyposis in 2030

4 Executive Summary of Familial Adenomatous Polyposis

5 Disease Background and Overview
5.1 Introduction
5.2 Etiology
5.3 Clinical Manifestations
5.4 Subtypes of FAP
5.5 Pathophysiology
5.6 Diagnosis

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Prevalent Patient Population of Familial Adenomatous Polyposis
6.3 Assumption and Rationale
6.4 The United States
6.4.1 Prevalent Cases of Familial Adenomatous Polyposis in the United States
6.4.2 Prevalent cases of FAP based on mutation in the United States
6.4.3 Type-specific Prevalence of Familial Adenomatous Polyposis in the United States
6.5 EU5
6.5.1 Germany
6.5.1.1 Prevalent Cases of Familial Adenomatous Polyposis in Germany
6.5.1.2 Prevalent cases of FAP based on mutation in Germany
6.5.1.3 Type-specific Prevalence of Familial Adenomatous Polyposis in Germany
6.5.2 France
6.5.2.1 Prevalent Cases of Familial Adenomatous Polyposis in France
6.5.2.2 Prevalent cases of FAP based on mutation in France
6.5.2.3 Type-specific Prevalence of Familial Adenomatous Polyposis in France
6.5.3 Italy
6.5.3.1 Prevalent Cases of Familial Adenomatous Polyposis in Italy
6.5.3.2 Prevalent cases of FAP based on mutation in Italy
6.5.3.3 Type-specific Prevalence of Familial Adenomatous Polyposis in Italy
6.5.4 Spain
6.5.4.1 Prevalent Cases of Familial Adenomatous Polyposis in Spain
6.5.4.2 Prevalent cases of FAP based on mutation in Spain
6.5.4.3 Type-specific Prevalence of Familial Adenomatous Polyposis in Spain
6.5.5 United Kingdom
6.5.5.1 Prevalent Cases of Familial Adenomatous Polyposis in the United Kingdom
6.5.5.2 Prevalent cases of FAP based on mutation in the United Kingdom
6.5.5.3 Type-specific Prevalence of Familial Adenomatous Polyposis in the United Kingdom
6.6 Japan
6.6.1 Prevalent Cases of Familial Adenomatous Polyposis in Japan
6.6.2 Prevalent cases of FAP based on mutation in Japan
6.6.3 Type-specific Prevalence of Familial Adenomatous Polyposis in Japan

7 Treatment and Management
7.1 Guidelines
7.1.1 American Society for Gastrointestinal Endoscopy Guidelines
7.1.2 European Society of Gastrointestinal Endoscopy (ESGE) guideline

8 Patient Journey

9 Case Report

10 Organizations contributing towards Familial Adenomatous Polyposis (FAP)

11 Emerging Therapies
11.1 Encapsulated Rapamycin (eRapa): Emtora Biosciences
11.1.1 Drug Descriptions
11.1.2 Other Developmental Activities
11.1.3 Clinical Development
11.1.4 Clinical Trials Information
11.1.5 Product Profile
11.2 Eflornithine/Sulindac: Cancer Prevention Pharmaceuticals
11.2.1 Drug Description
11.2.2 Other Developmental Activities
11.2.3 Clinical Development
11.2.4 Clinical Trials Information
11.2.5 Safety and Efficacy
11.2.6 Product Profile
11.3 Eicosapentaenoic acid: SLA Pharma
11.3.1 Drug Description
11.3.2 Clinical Development
11.3.3 Clinical Trials Information
11.3.4 Safety and Efficacy
11.3.5 Product Profile

12 Familial Adenomatous Polyposis: 7 Major Market Analysis
12.1 Key Findings
12.2 Market Size of Familial Adenomatous Polyposis in 7MM
12.3 Market Size of Familial Adenomatous Polyposis by Emerging Therapies
12.4 Market Size of Familial Adenomatous Polyposis by Current Therapies

13 Market Outlook
13.1 United States Market Size
13.1.1 Total Market Size of Familial Adenomatous Polyposis in United States
13.1.2 Market Size of Familial Adenomatous Polyposis by Therapies in United States
13.2 EU-5 Market Size
13.2.1 Germany
13.2.1.1 Total Market size of Familial Adenomatous Polyposis in Germany
13.2.1.2 Market Size of Familial Adenomatous Polyposis of Therapies in Germany
13.2.2 France
13.2.2.1 Total Market size of Familial Adenomatous Polyposis in France
13.2.2.2 Market Size of Familial Adenomatous Polyposis by Therapies in France
13.2.3 Italy
13.2.3.1 Total Market size of Familial Adenomatous Polyposis in Italy
13.2.3.2 Market Size of Familial Adenomatous Polyposis of Therapies in Italy
13.2.4 Spain
13.2.4.1 Total Market size of Familial Adenomatous Polyposis in Spain
13.2.4.2 Market Size of Familial Adenomatous Polyposis of Therapies in Spain
13.2.5 United Kingdom
13.2.5.1 Total Market size of Familial Adenomatous Polyposis in United Kindgom
13.2.5.2 Market Size of Familial Adenomatous Polyposis by Therapies in United Kingdom
13.3 Japan
13.3.1 Total Market size of Familial Adenomatous Polyposis in Japan
13.3.2 Market Size of Familial Adenomatous Polyposis of Therapies in Japan

14 Market Drivers

15 Market Barriers

16 SWOT Analysis

17 Unmet Needs

18 Appendix
18.1 Bibliography

19 Report Methodology

20 Publisher Capabilities

21 Disclaimer

22 About the Publisher

List of Tables
Table 1: Summary of Familial Adenomatous Polyposis, Market, Epidemiology, and Key Events (2018-2030)
Table 2: Diagnosed Prevalent Patient Population of Familial Adenomatous Polyposis in 7MM (2018-2030)
Table 3: Prevalent Cases of Familial Adenomatous Polyposis in the United States (2018-2030)
Table 4: Prevalent cases of FAP based on mutation in the United States (2018-2030)
Table 5: Type-specific Prevalence of Familial Adenomatous Polyposis in the United States (2018-2030)
Table 6: Prevalent Cases of Familial Adenomatous Polyposis in Germany (2018-2030)
Table 7: Prevalent cases of FAP based on mutation in Germany (2018-2030)
Table 8: Type-specific Prevalence of Familial Adenomatous Polyposis in Germany (2018-2030)
Table 9: Prevalent Cases of Familial Adenomatous Polyposis in France (2018-2030)
Table 10: Prevalent cases of FAP based on mutation in France (2018-2030)
Table 11: Type-specific Prevalence of Familial Adenomatous Polyposis in France (2018-2030)
Table 12: Prevalent Cases of Familial Adenomatous Polyposis in Italy (2018-2030)
Table 13: Etiology-specific Prevalence of Familial Adenomatous Polyposis in Italy (2018-2030)
Table 14: Type-specific Prevalence of Familial Adenomatous Polyposis in Italy (2018-2030)
Table 15: Prevalent Cases of Familial Adenomatous Polyposis in Spain (2018-2030)
Table 16: Prevalent cases of FAP based on mutation in Spain (2018-2030)
Table 17: Type-specific Prevalence of Familial Adenomatous Polyposis in Spain (2018-2030)
Table 18: Prevalent Cases of Familial Adenomatous Polyposis in the United Kingdom (2018-2030)
Table 19: : Prevalent cases of FAP based on mutation in the United Kingdom (2018-2030)
Table 20: Type-specific Prevalence of Familial Adenomatous Polyposis in United Kingdom (2018-2030)
Table 21: Prevalent Cases of Familial Adenomatous Polyposis in Japan (2018-2030)
Table 22: Prevalent cases of FAP based on mutation in Japan (2018-2030)
Table 23: Type-specific Prevalence of Familial Adenomatous Polyposis in Japan (2018-2030)
Table 24: Organizations contributing towards Familial Adenomatous Polyposis
Table 25: eRapa, Clinical Trial Description, 2021
Table 26: Eflornithine/Sulindac, Clinical Trial Description, 2021
Table 27: Eicosapentaenoic acid, Clinical Trial Description, 2021
Table 28: 7 Major Market Size of Familial Adenomatous Polyposis in USD Million (2018-2030)
Table 29: United States Market Size of Familial Adenomatous Polyposis by Emerging Therapies in USD Million (2018-2030)
Table 30: United States Market Size of Familial Adenomatous Polyposis by Emerging Therapies in USD Million (2018-2030)
Table 31: United States Market Size of Familial Adenomatous Polyposis in USD Million (2018-2030)
Table 32: United States Market Size of Familial Adenomatous Polyposis by Therapies in USD Million (2018-2030)
Table 33: Germany Market Size of Familial Adenomatous Polyposis in USD Million (2018-2030)
Table 34: Germany Market Size of Familial Adenomatous Polyposis by Therapies in USD Million (2018-2030)
Table 35: France Market Size of Familial Adenomatous Polyposis in USD Million (2018-2030)
Table 36: France Market Size of Familial Adenomatous Polyposis by Therapies in USD Million (2018-2030)
Table 37: Italy Market Size of Familial Adenomatous Polyposis in USD Million (2018-2030)
Table 38: Italy Market Size of Familial Adenomatous Polyposis by Therapies in USD Million (2018-2030)
Table 39: Spain Market Size of Familial Adenomatous Polyposis in USD Million (2018-2030)
Table 40: Spain Market Size of Familial Adenomatous Polyposis by Therapies in USD Million (2018-2030)
Table 41: United Kingdom Market Size of Familial Adenomatous Polyposis in USD Million (2018-2030)
Table 42: UK Market Size of Familial Adenomatous Polyposis by Therapies in USD Million (2018-2030)
Table 43: Japan Market Size of Familial Adenomatous Polyposis in USD Million (2018-2030)
Table 44: Japan Market Size of Familial Adenomatous Polyposis by Therapies in USD Million (2018-2030)

List of Figures
Figure 1: Endoscopic appearance of early FAP adenomas.
Figure 2: Illustrations of the extracolonic upper gastrointestinal polyp manifestations of FAP
Figure 3: Illustration of the extraintestinal manifestations of FAP
Figure 4: Prevalent Patient Population of Familial Adenomatous Polyposis in 7MM (2018-2030)
Figure 5: Prevalent Cases of Familial Adenomatous Polyposis in the United States (2018-2030)
Figure 6: Prevalent cases of FAP based on mutation in the US (2018-2030)
Figure 7: Type-specific Prevalence of Familial Adenomatous Polyposis in the United States (2018-2030)
Figure 8: Prevalent Cases of Familial Adenomatous Polyposis in Germany (2018-2030)
Figure 9: Prevalent cases of FAP based on mutation in Germany (2018-2030)
Figure 10: Type-specific Prevalence of Familial Adenomatous Polyposis in Germany (2018-2030)
Figure 11: Prevalent Cases of Familial Adenomatous Polyposis in France (2018-2030)
Figure 12: Prevalent cases of FAP based on mutation in France (2018-2030)
Figure 13: Type-specific Prevalence of Familial Adenomatous Polyposis in France (2018-2030)
Figure 14: Prevalent Cases of Familial Adenomatous Polyposis in Italy (2018-2030)
Figure 15: Prevalent cases of FAP based on mutation in Italy (2018-2030)
Figure 16: Type-specific Prevalence of Familial Adenomatous Polyposis in Italy (2018-2030)
Figure 17: Prevalent Cases of Familial Adenomatous Polyposis in Spain (2018-2030)
Figure 18: Prevalent cases of FAP based on mutation in Spain (2018-2030)
Figure 19: Type-specific Prevalence of Familial Adenomatous Polyposis in Spain (2018-2030)
Figure 20: Prevalent Cases of Familial Adenomatous Polyposis in the United Kingdom (2018-2030)
Figure 21: Prevalent cases of FAP based on mutation in the United Kingdom (2018-2030)
Figure 22: Type-specific Prevalence of Familial Adenomatous Polyposis in the United Kingdom (2018-2030)
Figure 23: Prevalent Cases of Familial Adenomatous Polyposis in Japan (2018-2030)
Figure 24: Prevalent cases of FAP based on mutation in Japan (2018-2030)
Figure 25: Type-specific Prevalence of Familial Adenomatous Polyposis in Japan (2018-2030)
Figure 26: 7 Major Market Size of Familial Adenomatous Polyposis in USD Million (2018-2030)
Figure 27: 7 Major Market Size of Familial Adenomatous Polyposis by Emerging Therapies in USD Million (2018-2030)
Figure 28: 7 Major Market Size of Familial Adenomatous Polyposis by Current Therapies in USD Million (2018-2030)
Figure 29: Market Size of Familial Adenomatous Polyposis in the United States, USD Million (2018-2030)
Figure 30: The United States Market Size of Familial Adenomatous Polyposis by Therapies in USD Million (2018-2030)
Figure 31: Market Size of Familial Adenomatous Polyposis in the Germany, USD Million (2018-2030)
Figure 32: The Germany Market Size of Familial Adenomatous Polyposis by Therapies in USD Million (2018-2030)
Figure 33: Market Size of Familial Adenomatous Polyposis in the France, USD Million (2018-2030)
Figure 34: The France Market Size of Familial Adenomatous Polyposis by Therapies in USD Million
Figure 35: Market Size of Familial Adenomatous Polyposis in the Italy, USD Million (2018-2030)
Figure 36: The Italy Market Size of Familial Adenomatous Polyposis of Therapies in USD Million (2018-2030)
Figure 37: Market Size of Familial Adenomatous Polyposis in the Spain, USD Million (2018-2030)
Figure 38: The Spain Market Size of Familial Adenomatous Polyposis of Therapies in USD Million
Figure 39: Market Size of Familial Adenomatous Polyposis in the United KIngdom, USD Million (2018-2030)
Figure 40: The United Kingdom Market Size of Familial Adenomatous Polyposis by Therapies in USD Million (2018-2030)
Figure 41: Market Size of Familial Adenomatous Polyposis in the Japan, USD Million (2018-2030)
Figure 42: The Japan Market Size of Familial Adenomatous Polyposis of Therapies in USD Million (2018-2030)
Note: Product cover images may vary from those shown
  • Emtora Biosciences
  • Cancer Prevention Pharmaceuticals
  • SLA Pharma
Note: Product cover images may vary from those shown
Adroll
adroll